Compare · HRMY vs JNJ
HRMY vs JNJ
Side-by-side comparison of Harmony Biosciences Holdings Inc. (HRMY) and Johnson & Johnson (JNJ): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both HRMY and JNJ operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- JNJ is the larger of the two at $610.38B, about 273.9x HRMY ($2.23B).
- JNJ has been more active in the news (16 items in the past 4 weeks vs 4 for HRMY).
- Both have 25 recent analyst ratings on file.
- Company
- Harmony Biosciences Holdings Inc.
- Johnson & Johnson
- Price
- $37.93-0.81%
- $255.53+0.88%
- Market cap
- $2.23B
- $610.38B
- 1M return
- -
- -5.45%
- 1Y return
- -
- +32.25%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2020
- News (4w)
- 4
- 16
- Recent ratings
- 25
- 25
Harmony Biosciences Holdings Inc.
Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, develops and commercializes therapies for patients with rare neurological disorders. Its product, WAKIX is a medication for the treatment of excessive daytime sleepiness in adult patients with narcolepsy in the United States. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is based in Plymouth Meeting, Pennsylvania.
Johnson & Johnson
Johnson & Johnson researches and develops, manufactures, and sells a range of products in the health care field worldwide. It operates through three segments: Consumer Health, Pharmaceutical, and Medical Devices. The Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; smoking cessation products under the NICORETTE brand; and acid reflux products under the PEPCID brand. This segment also provides women's health products, such as sanitary pads and tampons under the STAYFREE, CAREFREE, and o.b. brands; wound care products comprising adhesive bandages under the BAND-AID brand; and first aid products under the NEOSPORIN brand. The Pharmaceutical segment offers products in various therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, pulmonary hypertension, and cardiovascular and metabolic diseases. The Medical Devices segment provides electrophysiology products to treat cardiovascular diseases and neurovascular care products to treat hemorrhagic and ischemic stroke; orthopaedics products in support of hips, knees, trauma, spine, sports, and other; advanced and general surgery solutions that focus on breast aesthetics, ear, nose, and throat procedures; and disposable contact lenses and ophthalmic products related to cataract and laser refractive surgery under the ACUVUE brand. The company markets its products to general public, and retail outlets and distributors, as well as distributes directly to wholesalers, hospitals, and health care professionals for prescription use. Johnson & Johnson was founded in 1886 and is based in New Brunswick, New Jersey.
Latest HRMY
- Ladenburg Thalmann initiated coverage on Harmony Biosciences with a new price target
- SEC Form 8-K filed by Harmony Biosciences Holdings Inc.
- Harmony Biosciences Announces Planned CEO Transition to Support Next Phase of Growth
- Harmony Biosciences Announces Poster Presentation at the 17th European Narcolepsy Days
- CHIEF MEDICAL OFFICER Budur Kumar exercised 38,452 shares at a strike of $30.40 and sold $1,655,416 worth of shares (38,452 units at $43.05) as part of a pre-agreed trading plan (SEC Form 4)
- CHIEF MEDICAL OFFICER Budur Kumar exercised 22,954 shares at a strike of $30.49 and sold $1,453,169 worth of shares (33,954 units at $42.80) as part of a pre-agreed trading plan, decreasing direct ownership by 46% to 13,115 units (SEC Form 4)
- Harmony Biosciences to Participate in 2026 Cantor Global Healthcare Conference
- Wolfe Research initiated coverage on Harmony Biosciences with a new price target
- Harmony Biosciences to Participate in Piper Sandler Virtual CNS Symposium
- SEC Form 10-Q filed by Harmony Biosciences Holdings Inc.
Latest JNJ
- SEC Form 8-K filed by Johnson & Johnson
- Johnson & Johnson Announces Quarterly Dividend for Fourth Quarter 2026
- Johnson & Johnson reports Q3 2026 results, raises 2026 guidance
- TREMFYA® (guselkumab) demonstrated sustained clinical and endoscopic remission through 3 years in moderately to severely active Crohn's disease
- New TREMFYA® (guselkumab) study shows consistent perianal fistula remission across key Crohn's disease patient subgroups
- After a Record-Setting Week, Wall Street Turns to Inflation Data and the First Big Earnings Reports
- New Johnson & Johnson ICOTYDE® (icotrokinra) long-term data demonstrate robust 2-year results in the treatment of adults and adolescents with plaque psoriasis
- 2026 Takes a Promising Turn in the Fight Against Cancer as Five Advances Offer New Hope
- Johnson & Johnson announces new ICOTYDE® (icotrokinra) data in difficult-to-treat plaque psoriasis with proven durability through 2-years, affirming its use as a powerful first line systemic therapy
- New Global Survey by Johnson & Johnson Finds Most Women Don’t Connect Eye Health Changes with Menopause